Clinical trial
Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating…
NCT00433550 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00433550 |
|---|---|
| Title | Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer |
| Official title | A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH Pfizer Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, irinotecan hydrochloride, oxaliplatin |
| Enrollment | 33 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2014 |
| Completion | May 1, 2016 |
| First posted | Feb 12, 2007 |
| Last update posted | Aug 24, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: